KCM
IOVA icon

Knoll Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Knoll Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-97,100
Closed -$559K – 22
2015
Q3 		$559K Hold
97,100
– – 0.24% 15
2015
Q2 		$890K Sell
97,100
-2,900
-3% -$32.4K 0.29% 14
2015
Q1 		$1.21M Buy
+100,000
New +$1.13M 0.35% 10

Other funds holding IOVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Knoll Capital Management's IOVA Position: Q4 2015 in Review

Knoll Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2015, closing a stake of 97,100 shares — an estimated $559K sold.

Knoll Capital Management first reported a position in IOVA in Q1 2015 and held it in 3 quarters. The position peaked at $1.21M in Q1 2015. 82 funds tracked by Wall St. Rank hold IOVA as of Q4 2015.

  • Knoll Capital Management reported no remaining Iovance Biotherapeutics position as of Q4 2015 after selling out during the quarter.
  • Knoll Capital Management sold 97,100 Iovance Biotherapeutics shares in Q4 2015, an estimated $559K.
  • Knoll Capital Management first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 3 quarters.
  • Knoll Capital Management's Iovance Biotherapeutics position peaked at $1.21M in Q1 2015.
  • 82 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2015.

Based on Knoll Capital Management's 13F filing for Q4 2015, filed 17 Feb 2016.